Internal Medicine · Oklahoma City, OK
NPI
1982867693
Since 2008
Specialty
Internal Medicine
Code 207R00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
920 Stanton L Young Blvd
Oklahoma City, OK, 73104
Phone (405) 271-5963
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
625 services
Medicare patients, 2024
200
Average age 69
Drug cost, 2024
$4.0M
906 prescriptions
Company payments, 2025
$20.38
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohamad O Khawandanah was code 99215 (office e&m - established), 175 times for 91 patients. In total Mohamad O Khawandanah billed 625 services in 15 codes, and Medicare paid $51K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 175 | 91 | $100.52 | $18K |
| 99233 Hospital E&M - Subsequent | Facility | 130 | 31 | $88.25 | $11K |
| 99214 Office E&M - Established | Office | 108 | 79 | $60.79 | $6,566 |
| 99232 Hospital E&M - Subsequent | Facility | 80 | 25 | $58.53 | $4,682 |
| 99205 Office E&M - New | Office | 33 | 33 | $118.43 | $3,908 |
| 99231 Hospital E&M - Subsequent | Facility | 25 | 12 | $36.65 | $916 |
| 99213 Office E&M - Established | Office | 24 | 21 | $32.66 | $784 |
By year: 2022 $43K for 589 services; 2023 $57K for 711 services; 2024 $51K for 625 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohamad O Khawandanah prescribed most often to Medicare patients was Acyclovir, with 65 prescriptions and refills. In total Mohamad O Khawandanah wrote 906 Medicare prescriptions that cost $4.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 65 | 90 | 20 | $619 |
| Sprycel Dasatinib | 54 | 54 | Under 11 | $740K |
| Jakafi Ruxolitinib Phosphate | 38 | 38 | Under 11 | $525K |
| Imatinib Mesylate Generic | 33 | 33 | Under 11 | $11K |
| Allopurinol Generic | 32 | 40 | 20 | $108 |
| Levofloxacin Generic | 28 | 28 | 13 | $284 |
| Potassium Chloride Generic | 27 | 29 | 12 | $126 |
| Atovaquone Generic | 24 | 25 | Under 11 | $10K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 23 | 30 | Under 11 | $106 |
| Fluconazole Generic | 23 | 24 | Under 11 | $1,417 |
| Posaconazole Generic | 23 | 23 | Under 11 | $25K |
| Hydroxyurea Generic | 19 | 23 | Under 11 | $985 |
| Bosulif Bosutinib | 18 | 18 | Under 11 | $345K |
| Valacyclovir Valacyclovir Hcl | 17 | 23 | Under 11 | $1,075 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 16 | 16 | Under 11 | $395 |
Brand drugs: - claims; generic drugs: 603 claims; opioid claims: 48.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohamad O Khawandanah $20.38 ($20.38 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbvie Inc. with $20.38.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $20.38 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.